A Phase II study in adult patients with newly diagnosed chronic-phase chronic myeloid leukaemia of initial intensified imatinib therapy and sequential dose-escalation followed by treatment with nilotinib in suboptimal responders to determine the rate and duration of major molecular response

DOI number 10.58109/zn0q-1b28
Publisher Australasian Leukaemia and Lymphoma Group (ALLG)

Australasian Leukaemia and Lymphoma Group (ALLG)

Timothy Hughes (Institute of Medical and Veterinary Science)

Date Made Available 2023
Dataset Individual participant data (IPD) in aggregate form
Description of Dataset

Dataset includes

  • Data for 210 patients with newly diagnosed CML, introducing TKI in a sequential and randomised way.
  • Demographic data
  • Diagnostic data
  • Treatment data
  • Outcome data

Australasian Leukaemia and Lymphoma Group (ALLG)

Subject (ANZSRC Category)

Cancer therapy (excl. chemotherapy and radiation therapy)

Molecular targets

ANZCTR Reference ACTRN12607000325404
Dataset Access

Access can be requested via the Health Data Australia catalogue. Search for the ACTRN number in the catalogue to find datasets associated with this trial or email enquiries to info@allg.org.au